21-gene in Elder Breast Cancer Patients With Lymph Node Metastasis
This study is a single-center, bidirectional cohort study. It aims to include 35 elderly (≥65 years old) Luminal A type breast cancer patients with axillary lymph node metastasis after surgery as the research subjects. After signing the informed consent, the patients who meet the inclusion criteria will have their vari
| Condition(s) | Breast Cancer Metastatic, Breast Cancer Survival |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This study is a single-center, bidirectional cohort study. It aims to include 35 elderly (≥65 years old) Luminal A type breast cancer patients with axillary lymph node metastasis after surgery as the research subjects. After signing the informed consent, the patients who meet the inclusion criteria will have their various clinical and pathological data collected (preoperative imaging examinations, clinical and pathological information of the patients, basic disease conditions and medication strategies, surgical records, postoperative planned treatment plans and actual treatment situations, etc.), and their real adjuvant treatment situations (whether chemotherapy, radiotherapy, endocrine therapy, targeted therapy, etc. were performed after surgery) will be followed up and recorded. At the s |
| Who can participate | Inclusion Criteria: * Sign a written informed consent； * Female, age ≥ 65 years old； * Patients who have undergone radical surgery for breast cancer (radical surgery refers to modified radical mastectomy, radical mastectomy or simple mastectomy + axillary lymph node dissection), and have been histologically confirmed to have axillary lymph node metastasis after surgery； * Postoperative immunohistochemical typing and pTNM staging meet the following criteria: 1. Luminal A type (ER and PR positive with a positive rate ≥ 20%, Her-2 gene negative, Ki67 \< 15%), with pTNM staging of pTanyNanyM0. 2. Or Luminal B, Her-2 gene negative type, with ER and PR positive and a positive rate ≥ 20%, Ki67 ≤ 30%, and pTNM staging of pTanyN1M0. 3. Or age ≥ 70 years old, Luminal B, Her-2 gene negative type, wit |
| Ages | 65 Years |
| Sex | Female |
| Lead sponsor | Qilu Hospital of Shandong University |
| Locations | Jinan, Shandong, China |
| Start date | 2024-12-01 |
| NCT ID | NCT06891651 |
| Official listing | https://clinicaltrials.gov/study/NCT06891651 |